Remarks at Brookings on Drug Pricing

Alex M. Azar II

Brookings Institution

"Something has to change in how Medicare pays for physician-administered drugs. This is widely understood across the healthcare spectrum, and it’s been a long time coming. The only thing standing in the way is the one special interest that has benefited from this program far out of proportion to any other actor, for the last 15 years: the pharmaceutical industry."